Urine Extracellular Vesicle miRNA Changes Induced by Vicadrostat with/Without Empagliflozin in Patients with Chronic Kidney Disease.

ABSTRACT: Vicadrostat, a selective aldosterone synthase inhibitor, reduced albuminuria with concurrent renin-angiotensin system inhibition and empagliflozin, suggesting additive efficacy for chronic kidney disease (CKD) treatment. Specific urinary extracellular vesicle microRNAs (uEV miRNAs) may reflect key mechanisms of kidney injury. We investigated how vicadrostat alone or with empagliflozin affected uEV miRNA expression in study participants. Small RNA sequencing was conducted on uEV miRNAs from 435 participants with CKD who completed 14 weeks treatment in the phase II trial of vicadrostat given with or without empagliflozin. Differentially expressed uEV miRNAs in participants with ≥30% UACR (urine albumin-creatinine ratio) reduction treated with 10 or 20 mg vicadrostat were pooled and evaluated

SUBMITTER: Delic D 

PROVIDER: S-EPMC12652424 | biostudies-literature | 2025 Nov

REPOSITORIES: biostudies-literature